SEC Comment Letter 0000000000-24-013087 to Bon Natural Life Ltd (BON)
Bon Natural Life Ltd
Date: Nov. 26, 2024 · CIK: 0001816815 · Accession: 0000000000-24-013087
AI Filing Summary & Sentiment
File numbers found in text: 333-283333
Letter
November 26, 2024 Yongwei Hu Chief Executive Officer Bon Natural Life Limited C601, Gazelle Valley, No.69 Jinye Road Xi’an Hi-tech Zone, Xi’an, China Re:Bon Natural Life Limited Registration Statement on Form F-1 Filed November 19, 2024 File No. 333-283333 Dear Yongwei Hu: We have conducted a limited review of your registration statement and have the following comments. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form F-1 Cover Page 1.Please revise your cover page heading to quantify the number of Ordinary Shares you are registering. Refer to item 501(b)(2) of Regulation S-K. 2.We note your disclosure on page 7 that "ordinary shares started to trade on the Nasdaq Capital Market under the ticker symbol “BON” since June 24, 2021." Please revise your cover page to disclose the markets for your securities. Refer to Item 501(b)(4) of Regulation S-K. Management Compensation, page 95 3.Please revise to disclose the compensation of your executive officers and directors for your most recently completed financial year. Refer to Item 6.B of Form 20-F.
November 26, 2024 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Daniel Crawford at 202-551-7767 or Joe McCann at 202-551-6262 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Cassi Olson, Esq.
Show Raw Text
November 26, 2024
Yongwei Hu
Chief Executive Officer
Bon Natural Life Limited
C601, Gazelle Valley, No.69 Jinye Road
Xi’an Hi-tech Zone, Xi’an, China
Re:Bon Natural Life Limited
Registration Statement on Form F-1
Filed November 19, 2024
File No. 333-283333
Dear Yongwei Hu:
We have conducted a limited review of your registration statement and have the
following comments.
Please respond to this letter by amending your registration statement and providing
the requested information. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information
you provide in response to this letter, we may have additional comments.
Registration Statement on Form F-1
Cover Page
1.Please revise your cover page heading to quantify the number of Ordinary Shares
you are registering. Refer to item 501(b)(2) of Regulation S-K.
2.We note your disclosure on page 7 that "ordinary shares started to trade on the Nasdaq
Capital Market under the ticker symbol “BON” since June 24, 2021." Please revise
your cover page to disclose the markets for your securities. Refer to Item 501(b)(4) of
Regulation S-K.
Management
Compensation, page 95
3.Please revise to disclose the compensation of your executive officers and directors for
your most recently completed financial year. Refer to Item 6.B of Form 20-F.
November 26, 2024
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence
of action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Daniel Crawford at 202-551-7767 or Joe McCann at 202-551-6262
with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Cassi Olson, Esq.